Many MDM2/MDMX inhibitors have been developed for cancer therapy (Qin et al., 2015; Wang et al., 2018a, b, 2019b; de Oliveira Ribeiro et al., 2020), and some of them are in clinical trials (Liu et al., 2019b; Rafal et al., 2019). Here, MDM2 is linked to cancer.